Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
|Videos|May 25, 2011
Donna Berry on the SME Initiative
Author(s)Donna L. Berry, PhD, RN
Donna Berry from Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Symptom Management Excellence Initiative
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Symptom Management Excellence Initiative that combines patient-reported data, multidisciplinary input, and evidence-based practice to implement standardized approaches to cancer symptom management.
Advertisement
Related to this article
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
Arlocabtagene autoleucel met the primary end point of overall response rate in the registrational phase 2 QUINTESSENTIAL trial.
Patients with triple-class–exposed relapsed/refractory multiple myeloma reported improvements in pain, fatigue, and functioning during up to 2 years of linvoseltamab.
Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5